AO-176 is a humanized anti-CD47 IgG2 antibody with a best-in-class profile. Our next-generation anti-CD47 antibody AO-176 is highly differentiated, with the potential to improve upon the safety and efficacy profile relative to other agents in this class of checkpoint inhibitors. AO-176 works by blocking the “don’t eat me” signal, the standard mechanism of anti-CD47 antibodies. Beyond blocking this signal, AO-176 also works by directly killing tumor cells. Importantly, AO-176 binds preferentially to tumor cells, instead of to normal cells, and binds even more potently to tumors in their acidic microenvironment (low pH).
AO-176 is in a Phase 1 clinical trial. This Phase 1 clinical trial is a multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity of AO-176 in patients with select solid tumors.
Additional information about this trial may be found at www.clinicaltrials.gov using the trial identification number NCT03834948.
Data presented on AO-176 at recent medical and scientific meetings can be found in the Newsroom.
Our next-generation anti-CD47 antibody AO-176 is highly differentiated with a best-in-class profile